Despite the tremendous progress that
photothermal therapy (PTT) has recently achieved, it still has a long way to go to gain the effective targeted photothermal ablation of
tumor cells. Driven by this need, we describe a new class of targeted photothermal therapeutic agents for
cancer cells with pH responsive bioimaging using near-infrared
dye (NIR) IR825, conjugated poly(
ethylene glycol)-g-poly(dimethylaminoethyl
methacrylate) (PEG-g-PDMA, PgP), and
hyaluronic acid (HA) anchored reduced
graphene oxide (rGO) hybrid nanoparticles. The obtained rGO nanoparticles (PgP/HA-rGO) showed pH-dependent fluorescence emission and excellent near-infrared (NIR) irradiation of
cancer cells targeted in vitro to provide cytotoxicity. Using intravenously administered PTT agents, the time-dependent in vivo
tumor target accumulation was exactly defined, presenting eminent photothermal conversion at 4 and 8 h post-injection, which was demonstrated from the ex vivo biodistribution of
tumors. These
tumor environment responsive hybrid nanoparticles generated photothermal heat, which caused dominant suppression of
tumor growth. The histopathological studies obtained by H&E staining demonstrated complete healing from malignant
tumor. In an area of limited successes in
cancer therapy, our translation will pave the road to design stimulus environment responsive targeted PTT agents for the safe eradication of devastating
cancer.